The US Food and Drug Administration (USFDA) has issued a warning letter dated July 10, 2026, to a clinical investigator associated with a bioequivalence study conducted at Alembic Pharmaceuticals' Vadodara bioequivalence facility in Gujarat, relating to informed consent form (ICF) procedures used during the study. Alembic disclosed that the observations pertain to documentation and process issues with the ICF, not to data integrity, and affirmed that the letter does not restrict operations at the bioequivalence facility or impose material financial impact at this stage. Investors reacted with concern, and Alembic's shares fell about 2% as the episode raised scrutiny over US regulatory compliance and potential delays in Abbreviated New Drug Application (ANDA) reviews, though the company maintains that its data reliability and core manufacturing operations remain unaffected. Sources: FDA Issues Warning Letter to Alembic Pharma's Clinical ... 𝐃𝐫.𝐏𝐚𝐫𝐢 𝐒's P...
- Get link
- X
- Other Apps